関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | Bromobenzene | HCID 7961 | — |
| 反応物 | 7-Azaspiro[3.5]nonan-2-yl-(4-cyclobutylpiperazin-1-yl)methanone | HCID 59333133 | — |
| 試薬 | Cesium carbonate | HCID 10796 | — |
| 触媒 | Binap, (A+-)- | HCID 634876 | — |
| 触媒 | Palladium (II) acetate | HCID 4144353 | — |
| 溶媒 | Toluene | HCID 1140 | — |
| 生成物 | (4-Cyclobutylpiperazin-1-yl)-(7-phenyl-7-azaspiro[3.5]nonan-2-yl)methanone | HCID 46212800 | 46.78% |
反応手順
cesium carbonate (123 mg, 0.38 mmol) was added to a solution of (4-cyclobutylpiperazin-1-yl)(7-azaspiro[3.5]nonan-2-yl)methanone (100 mg, 0.34 mmol), PdOAc2 (7.70 mg, 0.03 mmol), BINAP (42.7 mg, 0.07 mmol) and bromobenzene (56.6 mg, 0.36 mmol) in toluene (5 mL). The reaction mixture was heated to 110°C for 18hrs. The room temperature cooled down mixture was filtered over celite. The solvent was concentrated. The product was purified by preparative HPLC using a low pH shallow gradient method (Mobile phase: 20-40% B; A: H2O with 0.05% TFA , B: CH3CN, 25 min. run) on Luna 15 m, C8 (2), 21.2x250 mm Phenomenex reverse phase column to provide (4-cyclobutylpiperazin-1-yl)(7-phenyl-7-azaspiro[3.5]nonan-2-yl)methanone (59.0 mg, 46.8 %) as white solid. 1H NMR (400 MHz, CHLOROFORM- _d_ ) d ppm 1.60 - 1.75 (m, 4 H) 1.75 - 1.81 (m, 2 H) 1.81 - 1.95 (m, 2 H) 1.96 - 2.10 (m, 4 H) 2.10 - 2.20 (m, 2 H) 2.21 - 2.35 (m, 4 H) 2.71 (dq, _J_ =8.01, 7.75 Hz, 1 H) 3.00 - 3.11 (m, 2 H) 3.11 - 3.26 (m, 3 H) 3.31 - 3.42 (m, 2 H) 3.56 - 3.70 (m, 2 H) 6.82 (t, _J_ =7.23 Hz, 1 H) 6.93 (d, _J_ =7.81 Hz, 2 H) 7.18 - 7.29 (m, 2 H) HRMS _m/z_ calcd for C23H33N3O 368.26964 [M+H]+, found 368.26981. MS _m/z_ 368.3 [M+H]\+ (ES+)
情報源と証拠
| 出典データセット | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-2bde997c68344c96991dffb75b1f4b33 |
|---|
| 出典メモ | 750 AstraZeneca ELN dataset |
|---|